Navigation Links
Sequella and NIH Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications
Date:11/16/2009

ella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

About NIAID and NIH

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law. The content of this release does not necessarily represent the official views of the Na
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
2. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
3. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
4. Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
5. Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. Vet-Stem and Central Veterinary Research Labs of Dubai Sign Exclusive License
11. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Follow us ... steady popularity the world over, due to its ... in the marketplace is expected to come from ... developing countries. Several sub-Saharan countries in the African ... already implemented genetically engineered crop production strategies. Rising ...
(Date:9/23/2014)... , Sept. 23, 2014  Age Defying Dermatology ® ... , has become one of the first clinics in ... "picoseconds" aesthetic laser for tattoo removal. The treatment safely ... results. "For years, tattoo removal has been a lengthy, ... Noodleman. "This is an opportunity to erase tattoo pigment ...
(Date:9/23/2014)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... announce that its wholly owned subsidiary, Portage Pharmaceuticals ... its team for further development of its PPL-003 ... permeable peptide platform technology derived from human genes ... Ms. Holly Prentice ...
(Date:9/23/2014)... BOSTON, Mass. (PRWEB) September 23, 2014 ... driven by Semantic Web technology, was named in the ... by Gartner, Inc. , The report details key ... category. , According to Gartner analysts Michael Shanler ... help accelerate innovation activities, expose complex relationships with scientific ...
Breaking Biology Technology:Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2
... 17 PLC Systems Inc.,(AMEX: PLC ) today ... the,American Stock Exchange that would demonstrate its ability to ... that its common stock will be delisted from the ... to trade on the,over-the-counter bulletin board., As previously ...
... DNA2.0, the leading synthetic genomics company, announced today a significant ... interface, a customer-friendly site navigation, a database of published synthetic ... with a powerful resource for analyzing DNA and protein sequences. ... ...
... 17 Waters Corporation,(NYSE: WAT ) ... detection of melamine in,infant formula and liquid ... of Science and Technology (M.O.S.T.). The new ... with tandem,quadrupole mass spectrometry (UPLC/MS/MS) operated in ...
Cached Biology Technology:PLC Systems Expects Common Stock To Be Delisted From American Stock Exchange 2PLC Systems Expects Common Stock To Be Delisted From American Stock Exchange 3DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus 2Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of China's Ministry of Science and Technology 2
(Date:9/23/2014)... Health will award funds to support the next phase ... improve ways of predicting drug safety and effectiveness. Researchers ... human tissue chips and combine them into an integrated ... human body. Led by the National Center for Advancing ... at $17 million in 2014 with additional support over ...
(Date:9/23/2014)... Foundation scientists have published a study showing that ... task-specific movement for 4 weeks can retrain the ... foot drop stimulator as rehabilitation intervention may facilitate ... of the tibialis anterior demonstrates a training effect ... published online ahead of print on July 2 ...
(Date:9/23/2014)... cow rumens and termite guts for microbes that can ... of next-generation biofuels, but some of the best microbial ... researchers report. , Their study , reported in ... , is the first to use biochemical approaches to ... can digest fiber, breaking it down into simple sugars ...
Breaking Biology News(10 mins):NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3
... announces that a new market research report is available ... Industry http://www.reportlinker.com/p090669/Global-Flow-Cytometers-Industry.html ... in US$ Million. The report provides separate comprehensive analytics ... America. Annual estimates and forecasts are provided for the ...
... eye disorder characterized by progressive loss of vision that ... end stage. , In a ChIP-Seq based approach, the ... factor Crx (Cone-rod homeobox) in the expression of retina-specific ... visual perception. In-depth analysis of Crx mediated regulation in ...
... The 2010 Golf Atlanta charity golf tournament raised $105,000 in ... treatments and eventually a cure for pancreatic cancer. 2010 ... Crabapple Golf Club in Alpharetta, Ga., just north of Atlanta. ... a non-profit biomedical research facility in Phoenix, Ariz., working to ...
Cached Biology News:Reportlinker Adds Global Flow Cytometers Industry 2Reportlinker Adds Global Flow Cytometers Industry 3Reportlinker Adds Global Flow Cytometers Industry 4Reportlinker Adds Global Flow Cytometers Industry 5Reportlinker Adds Global Flow Cytometers Industry 6Reportlinker Adds Global Flow Cytometers Industry 7Reportlinker Adds Global Flow Cytometers Industry 8Reportlinker Adds Global Flow Cytometers Industry 9Transcription factor scan identifies genetic cause for inherited blindness 2Golf Atlanta charity tournament raises $105,000 for TGen research 2
... is a post-translational modification that plays ... including immune regulation, inflammation, cell-to-cell adhesion, ... developed two lectin based Glycoprotein Isolation ... Germ Agglutinin (WGA), that allow isolation ...
... Mini Trans-Blot cell and PowerPac Basic power supply ... membranes. The Mini Trans-Blot cell accommodates two 7.5 ... holder cassettes, modular electrode assembly, Bio-Ice cooling unit, ... fiber pads. The PowerPac basic power supply, 100-120 ...
... Lumat tube luminometer provides the sensitivity and ... luminometer. Advanced digital photon counting with selected ... of spectral demands. Equipped with up to ... suited for reporter gene assays as well ...
... This kit allows for rapid, convenient, and ... simple bind/wash/elute process utilizes a spin column ... beads for concentration of proteins which were ... are strong ion exchangers, offering high binding ...
Biology Products: